Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Vande Casteele, Niels"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 25
Tytuł:
Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study.
Autorzy:
Vande Casteele N; Division of Gastroenterology, Department of Medicine, University of California San Diego School of Medicine, La Jolla, California, USA.; Alimentiv, London, Ontario, Canada.
Sandborn WJ; Division of Gastroenterology, Department of Medicine, University of California San Diego School of Medicine, La Jolla, California, USA.
Feagan BG; Alimentiv, London, Ontario, Canada.
Vermeire S; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
Dulai PS; Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Yarur A; Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Roblin X; Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Priest-en-Jarez, France.
Ben-Horin S; Department of Gastroenterology, Sheba Medical Center, Tel HaShomer, and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Dotan I; Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel, and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Osterman MT; University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Rosario M; Takeda, Cambridge, Massachusetts, USA.
Osborn TM; Takeda, Chicago, Illinois, USA.
Panes J; Department of Gastroenterology, Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
Lindner D; Takeda, Zurich, Switzerland.
Agboton C; Takeda, Zurich, Switzerland.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2022 Aug; Vol. 56 (3), pp. 463-476. Date of Electronic Publication: 2022 Apr 27.
Typ publikacji:
Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Colitis, Ulcerative*/chemically induced
Colitis, Ulcerative*/drug therapy
Crohn Disease*/chemically induced
Crohn Disease*/drug therapy
Inflammatory Bowel Diseases*/pathology
Adult ; Antibodies, Monoclonal, Humanized ; Bayes Theorem ; Female ; Gastrointestinal Agents ; Humans ; Male ; Remission Induction ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Application of Artificial Intelligence to Clinical Practice in Inflammatory Bowel Disease - What the Clinician Needs to Know.
Autorzy:
Chen D; Medical Operations, Cleveland Clinic Foundation, Cleveland, OH, USA.; Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Fulmer C; Department of Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Gordon IO; Department of Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Syed S; Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, School of Medicine, University of Virginia, Charlottesville, VA, USA.; School of Data Science, University of Virginia, Charlottesville, VA, USA.
Stidham RW; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA.; Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.
Vande Casteele N; Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Qin Y; Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Falloon K; Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Cohen BL; Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Wyllie R; Medical Operations, Cleveland Clinic Foundation, Cleveland, OH, USA.; Department of Pediatric Gastroenterology, Hepatology, and Nutrition, Cleveland Clinic Foundation, Cleveland, OH, USA.
Rieder F; Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.; Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Pokaż więcej
Źródło:
Journal of Crohn's & colitis [J Crohns Colitis] 2022 Mar 14; Vol. 16 (3), pp. 460-471.
Typ publikacji:
Journal Article
MeSH Terms:
Colitis*
Inflammatory Bowel Diseases*/diagnosis
Inflammatory Bowel Diseases*/therapy
Artificial Intelligence ; Chronic Disease ; Diagnostic Imaging ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.
Autorzy:
Sedano R; Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada.; Alimentiv Inc., London, Ontario, Canada.
Hogan M; Alimentiv Inc., London, Ontario, Canada.
Nguyen TM; Alimentiv Inc., London, Ontario, Canada.
Chang J; Alimentiv Inc., London, Ontario, Canada.
Zou GY; Alimentiv Inc., London, Ontario, Canada.; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
Macdonald JK; Alimentiv Inc., London, Ontario, Canada.
Vande Casteele N; Alimentiv Inc., London, Ontario, Canada.; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Hanzel J; Alimentiv Inc., London, Ontario, Canada.; Department of Gastroenterology, UMC Ljubljana, Ljubljana, Slovenia.
Crowley E; Alimentiv Inc., London, Ontario, Canada.; Division of Pediatric Gastroenterology, Western University, Children's Hospital, London Health Sciences Centre, London, Ontario, Canada.
Battat R; Jill Roberts Center for IBD, Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY, USA.
Dulai PS; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Singh S; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
D'Haens G; Alimentiv Inc., London, Ontario, Canada.; Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam Gastroenterology and Metabolism Research Institute, University of Amsterdam, Amsterdam, The Netherlands.
Sandborn W; Alimentiv Inc., London, Ontario, Canada.; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Feagan BG; Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada.; Alimentiv Inc., London, Ontario, Canada.; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
Ma C; Alimentiv Inc., London, Ontario, Canada.; Division of Gastroenterology & Hepatology, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Jairath V; Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada.; Alimentiv Inc., London, Ontario, Canada.; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
Pokaż więcej
Źródło:
Journal of Crohn's & colitis [J Crohns Colitis] 2022 Feb 23; Vol. 16 (2), pp. 224-243.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Colitis, Ulcerative*/drug therapy
Adult ; Humans ; Immunosuppressive Agents/therapeutic use ; Induction Chemotherapy ; Maintenance Chemotherapy ; Remission Induction
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Systematic review: disease activity indices for immune checkpoint inhibitor-associated enterocolitis.
Autorzy:
Ma C; Division of Gastroenterology & Hepatology, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Alimentiv Inc (formerly Robarts Clinical Trials), London, ON, Canada.
MacDonald JK; Alimentiv Inc (formerly Robarts Clinical Trials), London, ON, Canada.
Nguyen TM; Alimentiv Inc (formerly Robarts Clinical Trials), London, ON, Canada.
Chang J; Alimentiv Inc (formerly Robarts Clinical Trials), London, ON, Canada.
Vande Casteele N; Alimentiv Inc (formerly Robarts Clinical Trials), London, ON, Canada.; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Feagan BG; Alimentiv Inc (formerly Robarts Clinical Trials), London, ON, Canada.; Division of Gastroenterology and Department of Epidemiology and Biostatistics, Western University, London, ON, Canada.
Jairath V; Alimentiv Inc (formerly Robarts Clinical Trials), London, ON, Canada.; Division of Gastroenterology and Department of Epidemiology and Biostatistics, Western University, London, ON, Canada.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2022 Jan; Vol. 55 (2), pp. 178-190. Date of Electronic Publication: 2021 Nov 25.
Typ publikacji:
Journal Article; Systematic Review
MeSH Terms:
Colitis, Ulcerative*/physiopathology
Crohn Disease*/physiopathology
Enterocolitis*/chemically induced
Enterocolitis*/physiopathology
Humans ; Immune Checkpoint Inhibitors/adverse effects ; Severity of Illness Index
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis.
Autorzy:
Linggi B; Alimentiv, Inc, 100 Dundas St, Suite 200, London, ON, N6A 5B6, Canada.
Jairath V; Alimentiv, Inc, 100 Dundas St, Suite 200, London, ON, N6A 5B6, Canada.; Department of Medicine, University of Western Ontario, London, ON, Canada.; Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON, Canada.
Zou G; Alimentiv, Inc, 100 Dundas St, Suite 200, London, ON, N6A 5B6, Canada.; Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON, Canada.
Shackelton LM; Alimentiv, Inc, 100 Dundas St, Suite 200, London, ON, N6A 5B6, Canada.
McGovern DPB; F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.
Salas A; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Casanova, 143 08036, Barcelona, Spain.
Verstockt B; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Oude Markt 13, 3000, Leuven, Belgium.; Department of Chronic Diseases, Metabolism and Ageing, Translational Research in Gastrointestinal Disorders (TARGID) - IBD Unit, KU Leuven, Leuven, Belgium.
Silverberg MS; Mount Sinai Hospital Inflammatory Bowel Disease Centre, University of Toronto, 600 University Ave, Toronto, ON, M5G 1X5, Canada.
Nayeri S; Zane Cohen Centre for Digestive Diseases, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, 600 University Ave, Toronto, ON, M5G 1X5, Canada.
Feagan BG; Alimentiv, Inc, 100 Dundas St, Suite 200, London, ON, N6A 5B6, Canada.; Department of Medicine, University of Western Ontario, London, ON, Canada.; Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON, Canada.
Vande Casteele N; Alimentiv, Inc, 100 Dundas St, Suite 200, London, ON, N6A 5B6, Canada. .; Division of Gastroenterology, Department of Medicine, University of California San Diego, IBD Center, 9500 Gilman Drive #0956, La Jolla, CA, 92093, USA. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 Sep 14; Vol. 11 (1), pp. 18243. Date of Electronic Publication: 2021 Sep 14.
Typ publikacji:
Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Transcriptome*
Colitis, Ulcerative/*genetics
Aquaporins/genetics ; Aquaporins/metabolism ; Colitis, Ulcerative/metabolism ; Colitis, Ulcerative/pathology ; Colon/metabolism ; Cytokines/genetics ; Cytokines/metabolism ; Down-Regulation ; Humans ; Lipocalin-2/genetics ; Lipocalin-2/metabolism ; Protein Interaction Maps
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study.
Autorzy:
Battat R; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.; Division of Gastroenterology and Hepatology, Jill Roberts Center for IBD, Weill Cornell Medicine, New York, NY, USA.
Vande Casteele N; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.; Alimentiv Inc. (formerly Robarts Clinical Trials Inc.), London, ON, Canada.
Pai RK; Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale, AZ, USA.
Wang Z; Alimentiv Inc. (formerly Robarts Clinical Trials Inc.), London, ON, Canada.
Zou G; Alimentiv Inc. (formerly Robarts Clinical Trials Inc.), London, ON, Canada.; Department of Epidemiology and Biostatistics, Western University, London, ON, Canada.
McDonald JWD; Alimentiv Inc. (formerly Robarts Clinical Trials Inc.), London, ON, Canada.
Duijvestein M; Alimentiv Inc. (formerly Robarts Clinical Trials Inc.), London, ON, Canada.; Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands.
Jeyarajah J; Alimentiv Inc. (formerly Robarts Clinical Trials Inc.), London, ON, Canada.
Parker CE; Alimentiv Inc. (formerly Robarts Clinical Trials Inc.), London, ON, Canada.
Van Viegen T; Alimentiv Inc. (formerly Robarts Clinical Trials Inc.), London, ON, Canada.
Nelson SA; Alimentiv Inc. (formerly Robarts Clinical Trials Inc.), London, ON, Canada.
Boland BS; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Singh S; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Dulai PS; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Valasek MA; Department of Pathology, University of California San Diego, La Jolla, CA, USA.
Feagan BG; Alimentiv Inc. (formerly Robarts Clinical Trials Inc.), London, ON, Canada.; Department of Medicine, Western University, London, ON, Canada.
Jairath V; Alimentiv Inc. (formerly Robarts Clinical Trials Inc.), London, ON, Canada.; Department of Medicine, Western University, London, ON, Canada.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.; Alimentiv Inc. (formerly Robarts Clinical Trials Inc.), London, ON, Canada.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2020 Nov; Vol. 52 (10), pp. 1574-1582. Date of Electronic Publication: 2020 Sep 27.
Typ publikacji:
Evaluation Study; Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Colitis, Ulcerative/*pathology
Colon, Sigmoid/*pathology
Histological Techniques/*standards
Inflammation/*pathology
Rectum/*pathology
Adult ; Biopsy/methods ; Biopsy/standards ; Calibration ; Cohort Studies ; Colitis, Ulcerative/diagnosis ; Female ; Histological Techniques/methods ; Histological Techniques/statistics & numerical data ; Humans ; Inflammation/diagnosis ; Male ; Middle Aged ; Patient Participation ; Prospective Studies ; Reoperation/methods ; Reoperation/standards ; Reoperation/statistics & numerical data ; Reproducibility of Results ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
Autorzy:
Lefevre PLC; Robarts Clinical Trials, Inc., London, ON, Canada.
Vande Casteele N; Robarts Clinical Trials, Inc., London, ON, Canada.; IBD Center, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Pokaż więcej
Źródło:
Journal of Crohn's & colitis [J Crohns Colitis] 2020 Aug 01; Vol. 14 (Supplement_2), pp. S725-S736.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Inflammatory Bowel Diseases/*drug therapy
Janus Kinase Inhibitors/*therapeutic use
Heterocyclic Compounds, 3-Ring/adverse effects ; Heterocyclic Compounds, 3-Ring/pharmacology ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Humans ; Janus Kinase Inhibitors/adverse effects ; Janus Kinase Inhibitors/pharmacology ; Piperidines/pharmacology ; Piperidines/therapeutic use ; Pyrazoles/adverse effects ; Pyrazoles/pharmacology ; Pyrazoles/therapeutic use ; Pyridines/adverse effects ; Pyridines/pharmacology ; Pyridines/therapeutic use ; Pyrimidines/adverse effects ; Pyrimidines/pharmacology ; Pyrimidines/therapeutic use ; Pyrroles/adverse effects ; Pyrroles/pharmacology ; Pyrroles/therapeutic use ; Triazoles/adverse effects ; Triazoles/pharmacology ; Triazoles/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Letter: combination of biologics in inflammatory bowel diseases. Authors' reply.
Autorzy:
Yang E; Division of Gastroenterology, Department of Medicine, UCSD Inflammatory Bowel Disease Center, La Jolla, CA, USA.
Panaccione N; Faculty of Health Science, Western University, London, ON, Canada.
Whitmire N; Division of Gastroenterology, Department of Medicine, UCSD Inflammatory Bowel Disease Center, La Jolla, CA, USA.
Dulai PS; Division of Gastroenterology, Department of Medicine, UCSD Inflammatory Bowel Disease Center, La Jolla, CA, USA.
Vande Casteele N; Division of Gastroenterology, Department of Medicine, UCSD Inflammatory Bowel Disease Center, La Jolla, CA, USA.
Singh S; Division of Gastroenterology, Department of Medicine, UCSD Inflammatory Bowel Disease Center, La Jolla, CA, USA.
Boland BS; Division of Gastroenterology, Department of Medicine, UCSD Inflammatory Bowel Disease Center, La Jolla, CA, USA.
Collins A; Division of Gastroenterology, Department of Medicine, UCSD Inflammatory Bowel Disease Center, La Jolla, CA, USA.
Sandborn WJ; Division of Gastroenterology, Department of Medicine, UCSD Inflammatory Bowel Disease Center, La Jolla, CA, USA.
Panaccione R; Division of Gastroenterology, Department of Medicine, University of Calgary Inflammatory Bowel Disease Center, Calgary, AB, Canada.
Battat R; Division of Gastroenterology, Department of Medicine, UCSD Inflammatory Bowel Disease Center, La Jolla, CA, USA.; Division of Gastroenterology and Hepatology, Weill Cornell Medicine, Jill Roberts Center for Inflammatory Bowel Disease, New York, NY, USA.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2020 Aug; Vol. 52 (3), pp. 568-569.
Typ publikacji:
Letter; Comment
MeSH Terms:
Biological Products*
Crohn Disease*
Inflammatory Bowel Diseases*
Humans
Opinia redakcyjna
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis.
Autorzy:
Paul S; Department of Immunology, CIC1408, GIMAP EA3064, Université Jean Monnet, Saint Étienne, France.
Marotte H; Department of Rheumatology, SAINBOISE AINBIOSE INSERM 1059, University of Lyon, Saint-Étienne, France.
Kavanaugh A; Division of Rheumatology, Allergy & Immunology, University of California San Diego School of Medicine, La Jolla, California, USA.
Goupille P; Department of Rheumatology, University Hospital of Tours, EA 7501, Tours, France.
Kvien TK; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
de Longueville M; UCB Pharma, Brussels, Belgium.
Mulleman D; Department of Rheumatology, University Hospital of Tours, EA 7501, Tours, France.
Sandborn WJ; Department of Medicine, University of California San Diego, La Jolla, California, USA.
Vande Casteele N; Department of Medicine, University of California San Diego, La Jolla, California, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2020 Jul; Vol. 13 (4), pp. 743-751. Date of Electronic Publication: 2020 Apr 01.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antirheumatic Agents/*pharmacokinetics
Arthritis, Rheumatoid/*drug therapy
Certolizumab Pegol/*pharmacokinetics
Drug Monitoring/*methods
Adult ; Aged ; Antirheumatic Agents/administration & dosage ; Arthritis, Rheumatoid/blood ; Arthritis, Rheumatoid/diagnosis ; Certolizumab Pegol/administration & dosage ; Dose-Response Relationship, Drug ; Feasibility Studies ; Female ; Humans ; Male ; Middle Aged ; ROC Curve ; Randomized Controlled Trials as Topic ; Severity of Illness Index ; Treatment Outcome ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
Autorzy:
Yang E; UCSD Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, La Jolla, CA, USA.
Panaccione N; Faculty of Health Science, Western University, London, ON, Canada.
Whitmire N; UCSD Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, La Jolla, CA, USA.
Dulai PS; UCSD Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, La Jolla, CA, USA.
Vande Casteele N; UCSD Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, La Jolla, CA, USA.
Singh S; UCSD Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, La Jolla, CA, USA.
Boland BS; UCSD Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, La Jolla, CA, USA.
Collins A; UCSD Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, La Jolla, CA, USA.
Sandborn WJ; UCSD Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, La Jolla, CA, USA.
Panaccione R; University of Calgary Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Calgary, AB, Canada.
Battat R; UCSD Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, La Jolla, CA, USA.; Jill Roberts Center for IBD, Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY, USA.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2020 Jun; Vol. 51 (11), pp. 1031-1038. Date of Electronic Publication: 2020 Apr 24.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Drug Resistance*/drug effects
Drug Therapy, Combination*/adverse effects
Biological Products/*administration & dosage
Biological Products/*adverse effects
Crohn Disease/*drug therapy
Adalimumab/administration & dosage ; Adalimumab/adverse effects ; Adolescent ; Adult ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Certolizumab Pegol/administration & dosage ; Certolizumab Pegol/adverse effects ; Cohort Studies ; Crohn Disease/diagnostic imaging ; Crohn Disease/metabolism ; Endoscopy, Gastrointestinal ; Female ; Gastrointestinal Agents/administration & dosage ; Gastrointestinal Agents/adverse effects ; Humans ; Infliximab/administration & dosage ; Infliximab/adverse effects ; Male ; Middle Aged ; Remission Induction ; Retrospective Studies ; Treatment Failure ; Treatment Outcome ; Ustekinumab/administration & dosage ; Ustekinumab/adverse effects ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis.
Autorzy:
Dulai PS; Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Singh S; Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Jairath V; Department of Medicine, University of Western Ontario, London, ON, Canada.
Ma C; Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada.
Narula N; Division of Gastroenterology, McMaster University, Hamilton, Ontario, Canada.
Vande Casteele N; Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Peyrin-Biroulet L; Nancy University Hospital, Nancy, France.
Vermeire S; Division of Gastroenterology, University Hospitals Leuven, Leuven, Belgium.
D'Haens G; Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands.
Feagan BG; Department of Medicine, University of Western Ontario, London, ON, Canada.
Sandborn WJ; Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2020 Feb; Vol. 51 (4), pp. 435-445. Date of Electronic Publication: 2019 Nov 22.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Patient Reported Outcome Measures*
Colitis, Ulcerative/*diagnosis
Colitis, Ulcerative/*drug therapy
Colitis, Ulcerative/*epidemiology
Gastrointestinal Agents/*therapeutic use
Adult ; Aged ; Antibodies, Monoclonal, Humanized/therapeutic use ; Clinical Trials as Topic/statistics & numerical data ; Cohort Studies ; Colitis, Ulcerative/pathology ; Endoscopy, Gastrointestinal/statistics & numerical data ; Female ; Gastrointestinal Hemorrhage/epidemiology ; Humans ; Induction Chemotherapy/statistics & numerical data ; Infliximab/therapeutic use ; Maintenance Chemotherapy/statistics & numerical data ; Male ; Middle Aged ; Piperidines/therapeutic use ; Prevalence ; Pyrimidines/therapeutic use ; Pyrroles/therapeutic use ; Remission Induction ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases.
Autorzy:
Singh S; Division of Gastroenterology, University of California San Diego, La Jolla, California.; Division of Biomedical Informatics, University of California San Diego, La Jolla, California.
Dulai PS; Division of Gastroenterology, University of California San Diego, La Jolla, California.
Vande Casteele N; Division of Gastroenterology, University of California San Diego, La Jolla, California.
Battat R; Division of Gastroenterology, University of California San Diego, La Jolla, California.
Fumery M; Gastroenterology Unit, Amiens University and Hospital, Université de Picardie Jules Verne, Amiens, France.
Boland BS; Division of Gastroenterology, University of California San Diego, La Jolla, California.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, California.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2019 Oct; Vol. 50 (8), pp. 848-857. Date of Electronic Publication: 2019 Sep 04.
Typ publikacji:
Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms:
Antibodies, Monoclonal, Humanized/*blood
Gastrointestinal Agents/*blood
Inflammatory Bowel Diseases/*blood
Inflammatory Bowel Diseases/*drug therapy
Antibodies, Monoclonal, Humanized/therapeutic use ; Cohort Studies ; Drug Monitoring/methods ; Gastrointestinal Agents/therapeutic use ; Humans ; Inflammatory Bowel Diseases/diagnosis ; Prospective Studies ; Remission Induction/methods ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study.
Autorzy:
Vande Casteele N; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.; Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Baert F; Department of Gastroenterology, AZ Delta, Roeselare, Belgium.
Bian S; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Dreesen E; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Compernolle G; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Van Assche G; Translational Research in GastroIntestinal Disorders [TARGID], KU Leuven, Leuven, Belgium.; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Ferrante M; Translational Research in GastroIntestinal Disorders [TARGID], KU Leuven, Leuven, Belgium.; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Vermeire S; Translational Research in GastroIntestinal Disorders [TARGID], KU Leuven, Leuven, Belgium.; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Gils A; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Pokaż więcej
Źródło:
Journal of Crohn's & colitis [J Crohns Colitis] 2019 Sep 27; Vol. 13 (10), pp. 1248-1256.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Adalimumab/*blood
Anti-Inflammatory Agents/*blood
Crohn Disease/*drug therapy
Adalimumab/administration & dosage ; Adalimumab/pharmacokinetics ; Adalimumab/therapeutic use ; Adult ; Anti-Inflammatory Agents/administration & dosage ; Anti-Inflammatory Agents/pharmacokinetics ; Anti-Inflammatory Agents/therapeutic use ; Drug Monitoring/methods ; Female ; Humans ; Injections, Subcutaneous ; Male ; Middle Aged ; Prospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Autorzy:
Ma C; Division of Gastroenterology & Hepatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.; Robarts Clinical Trials, Inc., London, Ontario, Canada.
Panaccione NR; Faculty of Health Science, Western University, London, Ontario, Canada.
Nguyen TM; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Guizzetti L; Robarts Clinical Trials, Inc., London, Ontario, Canada.
Parker CE; Robarts Clinical Trials, Inc., London, Ontario, Canada.
Hussein IM; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Vande Casteele N; Robarts Clinical Trials, Inc., London, Ontario, Canada.; Department of Medicine, University of California San Diego, La Jolla, California, USA.
Khanna R; Division of Gastroenterology, Western University, London, Ontario, Canada.
Dulai PS; Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
Singh S; Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
Feagan BG; Robarts Clinical Trials, Inc., London, Ontario, Canada.; Division of Gastroenterology, Western University, London, Ontario, Canada.; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
Jairath V; Robarts Clinical Trials, Inc., London, Ontario, Canada.; Division of Gastroenterology, Western University, London, Ontario, Canada.; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
Pokaż więcej
Źródło:
Journal of Crohn's & colitis [J Crohns Colitis] 2019 Sep 19; Vol. 13 (9), pp. 1201-1216.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Nocebo Effect*
Inflammatory Bowel Diseases/*complications
Colitis, Ulcerative/complications ; Colitis, Ulcerative/drug therapy ; Crohn Disease/complications ; Crohn Disease/drug therapy ; Gastrointestinal Agents/adverse effects ; Gastrointestinal Agents/therapeutic use ; Humans ; Inflammatory Bowel Diseases/drug therapy ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Editorial: assessing histological disease activity in Crohn's disease-a call for standardisation of mucosal biopsy location. Authors' reply.
Autorzy:
Vande Casteele N; Division of Gastroenterology, Department of Medicine, University of California San Diego, California.
Jairath V; Department of Medicine, Division of Gastroenterology, Western University, London, ON, Canada.; Department of Biostatistics and Epidemiology, Western University, London, ON, Canada.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2019 Jul; Vol. 50 (1), pp. 104-105.
Typ publikacji:
Editorial; Comment
MeSH Terms:
Crohn Disease*
Biopsy ; Humans ; Reference Standards ; Transcriptome
Opinia redakcyjna
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease.
Autorzy:
Ma C; Division of Gastroenterology & Hepatology, University of Calgary, Calgary, AB, Canada.; Robarts Clinical Trials, Inc., London, ON, Canada.
Lee JK; Division of Research, Kaiser Permanente Northern California, San Francisco, California.; Division of Gastroenterology, Kaiser Permanente Northern California, San Francisco, California.
Mitra AR; Critical Care Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Teriaky A; Division of Gastroenterology, Western University, London, ON, Canada.
Choudhary D; Division of Gastroenterology & Hepatology, University of Calgary, Calgary, AB, Canada.
Nguyen TM; Robarts Clinical Trials, Inc., London, ON, Canada.
Vande Casteele N; Department of Medicine, University of California San Diego, California.
Khanna R; Division of Gastroenterology, Western University, London, ON, Canada.
Panaccione R; Division of Gastroenterology & Hepatology, University of Calgary, Calgary, AB, Canada.
Feagan BG; Robarts Clinical Trials, Inc., London, ON, Canada.; Division of Gastroenterology, Western University, London, ON, Canada.; Department of Epidemiology and Biostatistics, Western University, London, ON, Canada.
Jairath V; Robarts Clinical Trials, Inc., London, ON, Canada.; Division of Gastroenterology, Western University, London, ON, Canada.; Department of Epidemiology and Biostatistics, Western University, London, ON, Canada.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2019 Jul; Vol. 50 (1), pp. 5-23. Date of Electronic Publication: 2019 May 23.
Typ publikacji:
Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms:
Anti-Inflammatory Agents/*therapeutic use
Inflammatory Bowel Diseases/*drug therapy
Janus Kinase Inhibitors/*therapeutic use
Anti-Inflammatory Agents/adverse effects ; Humans ; Janus Kinase Inhibitors/adverse effects ; Randomized Controlled Trials as Topic ; Remission Induction ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease.
Autorzy:
Novak G; Robarts Clinical Trials Inc, London, ON, Canada.; Department of Gastroenterology, Ljubljana University Medical Centre, University of Ljubljana, Ljubljana, Slovenia.
Stevens T; Inflammatory Bowel Disease Centre, Academic Medical Center, Amsterdam, The Netherlands.
Van Viegen T; Robarts Clinical Trials Inc, London, ON, Canada.
Bossuyt P; Imelda General Hospital, Bonheiden, Belgium.
Štabuc B; Department of Gastroenterology, Ljubljana University Medical Centre, University of Ljubljana, Ljubljana, Slovenia.
Jeyarajah J; Robarts Clinical Trials Inc, London, ON, Canada.
Zou G; Robarts Clinical Trials Inc, London, ON, Canada.; Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON, Canada.
Gaemers IC; Amsterdam UMC, University of Amsterdam, Tytgat Institute for Liver and Intestinal Research, Amsterdam, The Netherlands.
McKee TD; STTARR Innovation Centre, University Health Network, Toronto, ON, Canada.
Fu F; STTARR Innovation Centre, University Health Network, Toronto, ON, Canada.
Shackelton LM; Robarts Clinical Trials Inc, London, ON, Canada.
Khanna R; Robarts Clinical Trials Inc, London, ON, Canada.; Department of Medicine, University of Western Ontario, London, ON, Canada.
van den Brink GR; Inflammatory Bowel Disease Centre, Academic Medical Center, Amsterdam, The Netherlands.; Amsterdam UMC, University of Amsterdam, Tytgat Institute for Liver and Intestinal Research, Amsterdam, The Netherlands.
Sandborn WJ; Robarts Clinical Trials Inc, London, ON, Canada.; Department of Medicine, University of California San Diego, La Jolla, California.
Feagan BG; Robarts Clinical Trials Inc, London, ON, Canada.; Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON, Canada.; Department of Medicine, University of Western Ontario, London, ON, Canada.
Pai RK; Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, Arizona.
Jairath V; Robarts Clinical Trials Inc, London, ON, Canada.; Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON, Canada.; Department of Medicine, University of Western Ontario, London, ON, Canada.
Vande Casteele N; Robarts Clinical Trials Inc, London, ON, Canada.; Department of Medicine, University of California San Diego, La Jolla, California.
D'Haens G; Robarts Clinical Trials Inc, London, ON, Canada.; Inflammatory Bowel Disease Centre, Academic Medical Center, Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2019 Jun; Vol. 49 (11), pp. 1401-1409. Date of Electronic Publication: 2019 Apr 15.
Typ publikacji:
Journal Article
MeSH Terms:
Crohn Disease*/genetics
Crohn Disease*/metabolism
Crohn Disease*/pathology
Colon/*pathology
Ileum/*pathology
Adult ; Biopsy ; Calgranulin B/genetics ; Colon/metabolism ; Cytokines/genetics ; Female ; Humans ; Ileum/metabolism ; Male ; Middle Aged ; Platelet Endothelial Cell Adhesion Molecule-1/genetics ; RNA, Messenger/metabolism ; Transcriptome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Customized Use of Anti-Tumour Necrosis Factor-α Therapy During Pregnancy.
Autorzy:
Seow CH; Department of Medicine, University of Calgary, Alberta, Canada.
Vande Casteele N; Department of Medicine, University of California, San Diego, California, USA.
Panaccione R; Department of Medicine, University of Calgary, Alberta, Canada.
Pokaż więcej
Źródło:
Journal of Crohn's & colitis [J Crohns Colitis] 2018 Nov 15; Vol. 12 (11), pp. 1379-1380.
Typ publikacji:
Letter; Comment
MeSH Terms:
Immunotherapy*
Tumor Necrosis Factor-alpha*
Female ; Humans ; Infliximab ; Pregnancy
Opinia redakcyjna
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
Autorzy:
Singh S; Division of Gastroenterology, University of California San Diego, La Jolla, California.; Division of Biomedical Informatics, University of California San Diego, La Jolla, California.
George J; Department of Internal Medicine, Bridgeport Hospital-Yale New Haven Health, Bridgeport, Connecticut.
Boland BS; Division of Gastroenterology, University of California San Diego, La Jolla, California.
Vande Casteele N; Division of Gastroenterology, University of California San Diego, La Jolla, California.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, California.
Pokaż więcej
Źródło:
Journal of Crohn's & colitis [J Crohns Colitis] 2018 May 25; Vol. 12 (6), pp. 635-643.
Typ publikacji:
Journal Article; Meta-Analysis; Review; Systematic Review
MeSH Terms:
Biological Products/*therapeutic use
Colitis, Ulcerative/*drug therapy
Crohn Disease/*drug therapy
Gastrointestinal Agents/*therapeutic use
Tumor Necrosis Factor-alpha/*antagonists & inhibitors
Adalimumab/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Biological Products/adverse effects ; Certolizumab Pegol/therapeutic use ; Drug Resistance ; Gastrointestinal Agents/adverse effects ; Humans ; Infliximab/therapeutic use ; Retreatment ; Treatment Failure ; Ustekinumab/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis.
Autorzy:
Singh S; Division of Gastroenterology, University of California San Diego, La Jolla, California, United States of America.; Division of Biomedical Informatics, University of California San Diego, La Jolla, California, United States of America.
Facciorusso A; Gastroenterology Unit, Department of Medical Sciences, University of Foggia, Foggia, Italy.
Singh AG; Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, California, United States of America.
Vande Casteele N; Division of Gastroenterology, University of California San Diego, La Jolla, California, United States of America.
Zarrinpar A; Division of Gastroenterology, University of California San Diego, La Jolla, California, United States of America.; Institute for Diabetes and Metabolic Health, University of California, San Diego, La Jolla, California, United States of America.; VA San Diego Health Systems, La Jolla, California, United States of America.
Prokop LJ; Department of Library Services, Mayo Clinic, Rochester, Minnesota, United States of America.
Grunvald EL; Weight Management Program, Department of Medicine, University of California San Diego, La Jolla, California, United States of America.
Curtis JR; Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, California, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2018 May 17; Vol. 13 (5), pp. e0195123. Date of Electronic Publication: 2018 May 17 (Print Publication: 2018).
Typ publikacji:
Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; Systematic Review
MeSH Terms:
Inflammation/*complications
Inflammation/*immunology
Obesity/*complications
Tumor Necrosis Factor-alpha/*antagonists & inhibitors
Humans ; Inflammation/drug therapy ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 25

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies